# Validation of multiplex steroid hormone measurements in prostate cancer using plasma for multimodality biomarker studies

Gido Snaterse[1,a], Lisanne F van Dessel[2,a], Angela E Taylor[3], Jenny A Visser[1], Wiebke Arlt[3], Martijn P Lolkema[2], Johannes Hofland[1,*]

1. Department of Internal Medicine, Section of Endocrinology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands

2. Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands

3. Institute of Metabolism and System Research, University of Birmingham, Birmingham, United Kingdom

[a]These authors contributed equally to this work.

*Corresponding author

Address for correspondence: Johannes Hofland, Department of Internal Medicine, Erasmus MC, Rg5, Dr. Molewaterplein 40, 3015 GD, Rotterdam, The Netherlands. Tel.: +31 10 704 0446.

E-mail: j.hofland@erasmusmc.nl

**Running title:** Multiplex steroid measurements in prostate cancer

**Key words**: Steroids, Androgens, Testosterone, CellSave, LC-MS/MS

**General Abbreviations**

ANOVA          Analysis of variance

CRPC           Castration-resistant prostate cancer

CS             CellSave Preservative

CTC            Circulating tumour cell

ctDNA          circulating tumour DNA

DHEA           Dehydroepiandrosterone

DHT            5α-dihydrotestosterone

HC             Healthy Control

LC-MS/MS       Liquid-chromatography tandem mass spectrometry

LLOQ           Lower limits of quantification

mCRPC          Metastatic castration-resistant prostate cancer

MS             Mass spectrometry

MSP            Mechanically-separated plasma

MTBE           Methyl-tert butyl ether

PC             Prostate cancer

PBS-BSA        phosphate-buffered saline with bovine serum albumin

**ABSTRACT**

**Background**

Steroid hormones are essential signalling molecules in prostate cancer (PC). However, many studies

focusing on liquid biomarkers fail to take the hormonal status of these patients into account. Steroid

measurements are sensitive to bias caused by matrix effects, thus assessing potential matrix effects is an

important step in combining circulating tumour DNA analysis with hormone status.

**Methods**

We investigated the accuracy of multi-steroid hormone profiling in mechanically-separated plasma

(MSP) samples and in plasma from CellSave Preservative (CS) tubes, that are typically used to obtain

circulating tumour DNA (ctDNA), compared to measurements in serum. We performed multiplex steroid

profiling by liquid chromatography-tandem mass spectrometry (LC-MS/MS) in samples obtained from

ten healthy controls and ten castration-resistant prostate cancer (CRPC) patients.

**Results**

Steroid measurements were comparable between MSP and serum. A small but consistent decrease of 8

– 21% compared to serum was observed when using CS plasma, which was considered to be within the

acceptable margin. The minimal residual testosterone levels of CRPC patients could be sensitively

quantified in both MSP and CS samples.

**Conclusions**

We validated the use of MSP and CS samples for multi-steroid profiling by LC-MS/MS. The optimised use

of these samples in clinical trials will allow us to gain further insight into the steroid metabolism in PC

patients.

## INTRODUCTION

Prostate cancer (PC) is a steroid-hormone dependent disease where androgens play a pivotal role in the evolution of the disease. Targeting the androgen receptor (AR) signalling pathway through androgen deprivation therapy (ADT) in locally advanced and metastatic PC is a highly effective way to inhibit tumour growth[1]. However, tumour cells will eventually become resistant to these low androgen concentrations and show disease progression. Resistance mechanisms include AR modifications, like mutations and overexpression[2,3], and changes in androgen biosynthesis and metabolism, thereby increasing intratumoural androgen availability[4-6]. The continued importance of the androgen signalling pathway in castration-resistant prostate cancer (CRPC) is underlined by the survival benefits observed with second-line therapies such as the anti-androgen enzalutamide and adrenal steroidogenesis inhibitor abiraterone [7-10]. Circulating steroid levels are measured to verify efficacy of hormonal treatment and have a prognostic value in patients with PC[11-13].

The assessment of circulating steroid hormones relies heavily on sensitive, specific and accurate measurement techniques, especially at castrate levels. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) combines multi-steroid profiling capabilities with superior sensitivity and specificity[14,15] over older techniques[16,17], while maintaining high sample throughput[18,19]. Multi-steroid assays for LC-MS/MS have been successfully developed in recent years to improve the detection and diagnosis of disorders associated with abnormal steroid hormones concentrations[20-23].

Steroid measurements are predominantly performed in serum samples. Previous LC-MS/MS studies have shown that steroids can be quantified reliably across different blood matrices[24-26], but there are differences observed between plasma and serum, use of glass or plastic tubes in the analytic process, or when using tubes with different stabilizing agents or with gel-separators for blood collection[24-29].

Consequently, alternative collection tubes and extraction methods must be validated before they can

reliably be used for steroid profiling.

The use of CellSave (CS) Preservative tubes in population- and patient-based cohorts has grown as this

specialised 'cell-stabilizing' blood collection tube preserves both circulating tumour cells (CTCs) and cell-

free circulating tumour DNA (ctDNA)[30,31]. These biomarkers allow for the assessment of tumour cell

genomic characteristics such as genomic instability in these patients[32]. These samples are now

extensively collected in (cancer) biobanks and could potentially also be used to measure patient steroid

profiles.

Mechanical blood separation methods are similarly gaining popularity in clinical chemistry due to their

easy applicability compared to the use of a separation gel. The BD Vacutainer® Barricor™ is a

mechanically-separated plasma (MSP) tube, and it has shown no obvious bias in steroid hormone

measurements versus a gel-based plasma tube in a single study[33], but this was confined to a select

number of five steroids, warranting further investigation.

In this study, we aimed to determine if plasma obtained with MSP and CS tubes is suitable for multiplex

steroid profiling, which, if confirmed, would streamline biomaterial collection for ctDNA and steroid

profiling in cancer patients to the use of a single tube. To this end, we performed LC-MS/MS analysis on

plasma samples obtained with MSP and CS tubes in comparison to serum obtained with standard SST™ II

Advance Vacutainer® tubes, collecting blood from healthy control (HC) subjects and patients with

metastatic CRPC (mCRPC).

**MATERIALS AND METHODS**

*Subjects*

At the Erasmus MC Cancer Institute in Rotterdam, The Netherlands, healthy controls (HCs) and patients

were included within study EMC-2016-761, which was approved by the medical ethical committee of

our institute. HCs were all adult male subjects. Patients were adult subjects with mCRPC treated with

ADT. Patients were eligible to start treatment with or were currently treated with second-line hormonal

therapy (abiraterone with prednisone, enzalutamide or apalutamide). For all subjects the following

exclusion criteria were applied: 1) an endocrine disease with altered activity of the hypothalamic-

pituitary-adrenal or hypothalamic-pituitary-gonadal axis; and 2) the use of medications, excluding those

used to treat PC, that interfered with circulating steroid levels or dysregulated the hypothalamic-

pituitary-adrenal or hypothalamic-pituitary-gonadal axis. All subjects provided written informed consent

before any study procedure.

*Samples*

Blood was collected from HCs and mCRPC patients in SST™ II Advance Vacutainer® (serum; BD, Franklin

Lakes, NJ, USA), Vacutainer® Barricor™ (BD) and CellSave Preservative (Menarini Sillicon Biosystems Inc,

Huntington Valley, PA, USA) blood collection tubes. All samples were processed within 96 hours after

blood collection. All tubes were centrifuged at 1,711$g$ for 10 minutes at room temperature. Plasma from

CS tubes was subsequently centrifuged at 12,000$g$ for 10 minutes at 4°C. Samples were stored at -80°C

until extraction.

*Steroid extraction*

Calibration series (0.25 ng/mL – 500 ng/mL for HC, and 0.01 ng/mL – 500 ng/mL for mCRPC) were

prepared in phosphate buffered saline (PBS) with 0.1% bovine serum albumin (BSA) or in charcoal-

stripped pooled human serum (Goldenwest Diagnostics, Temecula, CA, USA). Steroids investigated were

17-hydroxyprogesterone, androstenedione, cortisol, cortisone, corticosterone, dehydroepiandrosterone

(DHEA), dihydrotestosterone (DHT) and testosterone. The stripped-serum calibration series was used to

quantify all steroids with the exception of androstenedione, due to a high background signal in stripped

serum but not in PBS-BSA. An internal standard solution was prepared in methanol/water 50/50 with

equal concentrations (1 μg/mL) of the following deuterated steroids: 17-hydroxyprogesterone-d8,

cortisol-d4, corticosterone-d8, DHEA-d6, DHT-d3, testosterone-d3. All steroids were obtained from

Sigma Aldrich, UK.

400 μL of sample was transferred to hexamethyldisilazane-treated (Thermo Fisher) glass tubes (VWR,

Amsterdam, The Netherlands). 20 μL of the internal standard solution was added and all samples were

thoroughly vortexed. Liquid-liquid extraction was performed as previously described[34] by adding 2 mL

methyl-tert butyl ether (MTBE, Sigma Aldrich, Zwijndrecht, The Netherlands) to each tube and vortexing.

The samples were left at room temperature for 30 minutes to allow phase separation. The upper

organic layer was transferred and the MTBE was evaporated under nitrogen at 50° C. The samples

underwent a second liquid-liquid extraction with 2 mL MTBE. Samples were reconstituted in 125 μL LC-

MS grade 50% methanol (CHROMASOLV, Sigma Aldrich, Zwijndrecht, The Netherlands) before

measurement.

*Steroid analysis by tandem mass spectrometry*

Steroid concentrations were measured by mass spectrometry (Xevo TQ-XS, Waters, Milford, MA, USA)

after injection of 20 µL sample volume and separation on an ACQUITY uPLC (Waters) with a Waters HSS

T3 column (2.1 mm x 50 mm, 1.8 µm, Waters)[35-39]. The mobile phases consisted of water (A) and

methanol (B) both with 0.1% formic acid and a 5-minute linear gradient was used (45 – 75% B) with a

flow rate of 0.6 mL/min. The multiple reaction monitoring settings and retention times of the LC-MS/MS

method were previously reported[36,38,39]. The method used represents an optimisation of these methods,

steroid transitions were re-tuned for optimum response. The updated reaction settings, retention times

and lower limits of quantification (LLOQ) can be found in **Supplementary Table 1** and a representative

chromatogram can be found in **Supplementary Figure 1.**

Steroids were quantified against the linear calibration series relative to an internal standard and were

only included in the final analysis if the calibration series $R^2$ was > 0.99 and appropriate lower limits of

quantification were reached. The LLOQ was set to the lowest calibration concentration that had a clearly

defined peak and a signal-to-noise ratio > 10. Samples with concentrations below the LLOQ were

detectable, but quantification was less accurate.

*Statistics*

LC-MS/MS raw data was processed using MassLynx (v4.1, Waters). Statistical analysis was performed

using GraphPad Prism (Version 6). Normality of the data was analysed with a D'Agostino & Pearson's

test. Comparisons of steroid hormone concentrations between the blood collection tubes were

performed with Bland-Altman difference analysis and repeat measurements 1-way ANOVA with post-

hoc Dunnett's test. Correlations in hormone levels were determined by Deming regression. Group

concentrations and differences are shown as mean ± SD, unless specified otherwise. P values were

considered significant if <0.05.

## RESULTS

**Comparison of blood collection tubes**

Baseline characteristics of the study participants are shown in **Table 1**. Circulating steroid levels of 8 steroids were determined by LC-MS/MS in plasma collected with CS and MSP tubes, respectively, and serum, all collected from 10 HCs and 10 mCRPC patients. Quantification and concentration ranges for the steroids are reported in **Table 2.** Most steroids could be quantified in HCs at the level of the lowest calibration sample (0.25 ng/mL), with the exception of androstenedione (0.5 ng/mL), DHEA (1 ng/mL) and DHT (1 ng/mL). Serum values below the LLOQ were detected for DHEA (HC: n = 1, mCRPC: n = 4), 17-hydroxyprogesterone (mCRPC: n = 2) and testosterone (mCRPC: n = 2) and excluded from further analysis.

The values observed in MSP samples were comparable to those found in serum samples for most steroids. The only exception was DHEA, which was higher (21.3 % ± 32.9 % p<0.05) in MSP samples than in serum (**Figure 1**). In CS samples, significantly lower concentrations compared to serum samples were observed for corticosterone (-16.2 % ± 15.2 %, p<0.001), 17-hydroxyprogesterone (-9.4 % ± 19.9 %, p<0.05), cortisol (-13.2 % ± 13.0 %, p<0.001), cortisone (-14.4 % ± 13.1 %, p<0.001), and androstenedione (-18.4 % ± 13.6 %, p<0.001). No significant differences were found for DHEA compared to serum**.**

Similar steroid concentrations between HC and mCRPC subjects were observed for corticosterone, cortisol and cortisone (**Figure 2**). Lower concentrations were observed for 17-hydroxyprogesterone, androstenedione, DHEA and testosterone in mCRPC subjects. This was likely due to a combination of castration (testosterone) and age-related effects, as the mCRPC subjects were older than the healthy control subjects.

Circulating androgen concentration in mCRPC patients are >10 fold lower than in healthy men due to

ADT, requiring highly sensitive techniques to accurately measure residual androgens. Therefore, the

calibration series was expanded to include lower concentrations (0.01 – 0.25 ng/mL) to allow

quantification of castrate testosterone levels. Accurate quantification at low concentration was

achieved, with an analytic LLOQ for testosterone of 0.1 nmol/L. Similar to the other steroids, lower

testosterone concentrations compared to serum were detected in CS samples, but not in MSP samples,

at normal HC concentrations (-11.5 % ± 2.8 %, p<0.001) and at castrate concentrations (-16.9 % ± 24.3 %,

p<0.05) (**Figure 1**). Low signal-to-noise ratios limited the reliability of DHT quantification which could not

be accurately quantified in the mCRPC subjects with our assay.

**Correlation of steroid measurements between matrices**

The correlations between results obtained in MSP and CS samples compared to those results obtained in

serum were independently determined by Deming regression (**Figure 3**). For DHT analysis only HC

samples were included. Corticosterone, DHEA and testosterone were normally distributed after log-

transformation. Significant correlations (all p<0.001) between both matrices and serum was observed

for 17-hydroxyprogesterone, androstenedione, corticosterone, cortisol, cortisone, DHEA and

testosterone. The analysis also revealed a poor correlation for DHT between CS and serum ($R^2$ = 0.60)

and between MSP and serum ($R^2$ = 0.45), whereas steroid concentrations measured in MSP and CS

samples, respectively, correlated more closely ($R^2$ = 0.89, y = 0.89x + 0.15) (data not shown).

**DISCUSSION**

In this study, we investigated whether MSP- or CS-derived plasma, samples that are abundantly present in biobanks obtained from PC patients, are suitable for multiplex steroid profiling by LC-MS/MS. We compared them to the current standard collection method using serum samples collected with SST™ II Advance Vacutainers®. We showed that measurements in MSP are equal to serum. When collecting plasma in CS tubes, steroid concentrations were 8-21% lower than measurements using serum or MSP. The Guideline on Bioanalytical Method Validation (2011) of the European Medicines Agency advises that accuracy must be within 15 % of the nominal concentration and within 20 % at the LLOQ[40]. The decreases observed for most steroids in CS plasma, using serum as a reference, were within this acceptable range (**Table 2**). Therefore, we conclude that CS plasma samples are suitable for steroid profiling, which can be combined with analysis of CTCs or ctDNA. However, caution is advised when interpreting results obtained in CS plasma samples against reference values that were obtained in serum, and direct comparison to samples collected in other tubes should be avoided. Nevertheless, these findings may reduce patient burden and open up the possibility to undertake detailed steroid profiling of large collections of biomaterial already collected for ctDNA analysis.

In this study, most steroids could be quantified accurately within the range of the calibration series. Most of the Δ4-steroids, such as cortisol or testosterone, ionise more easily and so can be accurately quantified at low levels (0.03 – 0.15 nM). This allows for the quantification of testosterone in mCRPC patients (typically <0.5nM)[11]. Δ5-steroids such as DHEA and saturated steroids such as DHT are poor ionisers and quantification at lower concentrations is beyond the sensitivity of the mass spectrometer[22]. Like testosterone, DHT levels are suppressed in castrated patients and the concentrations in these patients could not be accurately assessed. DHEA levels in men decline with age[41], and the mCRPC subjects in this study were older than the HC subjects. Consequently, values below the LLOQ were

detected in four mCRPC patients and were excluded from the analysis. Derivatization, for example to

form an oxime, increases ionisability, and therefore sensitivity allowing low level quantification of Δ5-

and 5α-reduced steroids[22]. However, the derivatization method is not suited for routine clinical

diagnostic measurements due to increased sample preparation time and cost. In addition to this,

fragmentation produces multiple derivatives for some steroids adding to the complexity of the analysis.

Matrix effects and cross-reactivity are established sources of interference in steroid hormone profile

studies with immunoassay and LC-MS/MS[24-29]. Previous studies have identified the type of blood sample

tube as a potential source of interference. MSP tubes like BD Vacutainer® Barricor™ utilise mechanical

separation of plasma, which makes them easily applicable, but the accuracy of steroid hormone

measurements in these tubes has not been fully validated yet. Our study shows that multiplex steroid

quantification in MSP samples is comparable to the serum collected with the reference tube, in line with

a previous study that detected no bias versus gel-based plasma tubes using an immunoassay platform[33].

The only significant difference between steroid measurements in MSP and serum related to DHEA.

Quantification of DHEA at low concentrations with LC-MS/MS remains a challenge as its structure

contributes to poor MS ionisation[22,42]. This challenge could be overcome by using a more sensitive mass

spectrometer or with the use of derivatization. Prior to using MSP tubes for clinical studies, however, full

validation considering accuracy, precision and recovery with larger sample size is recommended.

CS tubes are optimised for the measurement of circulating nucleic acids or tumour cells[30,31]. The use of

this matrix for liquid biopsies has increased exponentially over the last years due to the successful

genomic characterization of CTCs or free circulating nucleic acids, but no studies have investigated if

plasma from CS tubes are suitable for quantification of circulating steroid hormone levels. Our

experiments indicate that steroid measurements in CS samples are affected by a mild bias, which

resulted in an approximate 8 – 21% decrease compared to serum. We observed similar effects in both

HCs and mCRPC subjects. CS tubes contain 300 μL of $Na_2EDTA$ anticoagulant as well as an undisclosed

preservative to stabilise cells in the sample. Due to the presence of the $Na_2EDTA$ there may be an

inherent dilution of the sample, which amounts to approximately 3-4 % on a 7.5 – 10 mL volume. This

dilution factor is insufficient to account for the difference in circulating steroid hormone levels however,

and it is possible that other factors also contribute towards the observed difference.

This decrease was observed across a variety of different polarity steroids with different molecular

weights. It is therefore unlikely that the preservative co-elutes with one of the steroids and suppresses

the MS signal. Either there is an unidentified contaminant in the tubes which affects all steroids or the

steroids themselves are being retained/bound to the tube itself. Steroids have been long recognised to

bind to plastics[43], which may contribute to the lower values in the CS samples.

Currently, CS tubes are most commonly utilised in oncological studies to obtain CTCs and ctDNA.

Hormonal treatment options in breast- and prostate cancer involve potent suppression of oestrogens or

androgens. For example, inhibition of testicular steroidogenesis by ADT will typically lower testosterone

levels by >90 %[11]. Interpretation of such changes is unlikely to be affected by the difference observed in

CS samples. Especially within the context of a single study the relative difference should affect all

samples identically as long as a single collection tube is used. As such, the observed difference is

acceptable for most clinical purposes, including the use of CS samples for steroid profiling in PC patients.

Steroid profiles and analysis of CTCs or ctDNA investigation will decrease costs and reduce patient

burden.

In conclusion, MSP samples are suitable for steroid quantification, including castrate range of

androgens. Similarly, CS samples are suitable for steroid measurements, although there is a consistent

bias of 8 - 21% lower steroid hormone levels. Therefore, all samples in a research study should be

collected in the same sample tubes to avoid potential variation due to effects from the tubes

themselves.

**References**

1. Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. JAMA
2005;294:238-44.
2. Linja MJ, Savinainen KJ, Saramaki OR, Tammela TL, Vessella RL, Visakorpi T. Amplification and
overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res
2001;61:3550-5.
3. Taylor BS, Schultz N, Hieronymus H, et al. Integrative genomic profiling of human prostate
cancer. Cancer Cell 2010;18:11-22.
4. Stanbrough M, Bubley GJ, Ross K, et al. Increased expression of genes converting adrenal
androgens to testosterone in androgen-independent prostate cancer. Cancer Res 2006;66:2815-25.
5. Montgomery RB, Mostaghel EA, Vessella R, et al. Maintenance of intratumoral androgens in
metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res
2008;68:4447-54.
6. Mohler JL, Gregory CW, Ford OH, 3rd, et al. The androgen axis in recurrent prostate cancer. Clin
Cancer Res 2004;10:440-8.
7. Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after
chemotherapy. N Engl J Med 2012;367:1187-97.
8. de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic
prostate cancer. N Engl J Med 2011;364:1995-2005.
9. Fizazi K, Tran N, Fein L, et al. Abiraterone plus Prednisone in Metastatic, Castration-Sensitive
Prostate Cancer. N Engl J Med 2017;377:352-60.
10. Davis ID, Martin AJ, Stockler MR, et al. Enzalutamide with Standard First-Line Therapy in
Metastatic Prostate Cancer. N Engl J Med 2019;381:121-31.
11. Snaterse G, Visser JA, Arlt W, Hofland J. Circulating steroid hormone variations throughout
different stages of prostate cancer. Endocr Relat Cancer 2017;24:R403-R20.
12. Sakamoto S, Maimaiti M, Xu M, et al. Higher Serum Testosterone Levels Associated with
Favorable Prognosis in Enzalutamide- and Abiraterone-Treated Castration-Resistant Prostate Cancer. J
Clin Med 2019;8.
13. Attard G, Reid AH, A'Hern R, et al. Selective inhibition of CYP17 with abiraterone acetate is
highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol 2009;27:3742-8.
14. Wang C, Catlin DH, Demers LM, Starcevic B, Swerdloff RS. Measurement of total serum
testosterone in adult men: comparison of current laboratory methods versus liquid chromatography-
tandem mass spectrometry. J Clin Endocrinol Metab 2004;89:534-43.
15. Taieb J, Mathian B, Millot F, et al. Testosterone measured by 10 immunoassays and by isotope-
dilution gas chromatography-mass spectrometry in sera from 116 men, women, and children. Clin Chem
2003;49:1381-95.
16. Handelsman DJ, Newman JD, Jimenez M, McLachlan R, Sartorius G, Jones GR. Performance of
direct estradiol immunoassays with human male serum samples. Clin Chem 2014;60:510-7.
17. Krasowski MD, Drees D, Morris CS, Maakestad J, Blau JL, Ekins S. Cross-reactivity of steroid
hormone immunoassays: clinical significance and two-dimensional molecular similarity prediction. BMC
Clin Pathol 2014;14:33.
18. Taylor AE, Keevil B, Huhtaniemi IT. Mass spectrometry and immunoassay: how to measure
steroid hormones today and tomorrow. Eur J Endocrinol 2015;173:D1-12.
19. Monaghan PJ, Keevil BG, Trainer PJ. The use of mass spectrometry to improve the diagnosis and
the management of the HPA axis. Rev Endocr Metab Disord 2013;14:143-57.

20.    Arlt W, Lang K, Sitch AJ, et al. Steroid metabolome analysis reveals prevalent glucocorticoid
excess in primary aldosteronism. JCI Insight 2017;2.
21.    Arlt W, Biehl M, Taylor AE, et al. Urine steroid metabolomics as a biomarker tool for detecting
malignancy in adrenal tumors. J Clin Endocrinol Metab 2011;96:3775-84.
22.    Hakkinen MR, Murtola T, Voutilainen R, et al. Simultaneous analysis by LC-MS/MS of 22
ketosteroids with hydroxylamine derivatization and underivatized estradiol from human plasma, serum
and prostate tissue. J Pharm Biomed Anal 2019;164:642-52.
23.    Storbeck KH, Schiffer L, Baranowski ES, et al. Steroid metabolome analysis in disorders of
adrenal steroid biosynthesis and metabolism. Endocr Rev 2019.
24.    Coburn SB, Stanczyk FZ, Falk RT, et al. Comparability of serum, plasma, and urinary estrogen and
estrogen metabolite measurements by sex and menopausal status. Cancer Causes Control 2019;30:75-
86.
25.    Hepburn S, Wright MJ, Boyder C, et al. Sex steroid hormone stability in serum tubes with and
without separator gels. Clin Chem Lab Med 2016;54:1451-9.
26.    Raff H, Sluss PM. Pre-analytical issues for testosterone and estradiol assays. Steroids
2008;73:1297-304.
27.    Morovat A, James TS, Cox SD, et al. Comparison of Bayer Advia Centaur immunoassay results
obtained on samples collected in four different Becton Dickinson Vacutainer tubes. Ann Clin Biochem
2006;43:481-7.
28.    Smets EM, Dijkstra-Lagemaat JE, Blankenstein MA. Influence of blood collection in plastic vs.
glass evacuated serum-separator tubes on hormone and tumour marker levels. Clin Chem Lab Med
2004;42:435-9.
29.    Schouwers S, Brandt I, Willemse J, et al. Influence of separator gel in Sarstedt S-Monovette(R)
serum tubes on various therapeutic drugs, hormones, and proteins. Clin Chim Acta 2012;413:100-4.
30.    Rothwell DG, Smith N, Morris D, et al. Genetic profiling of tumours using both circulating free
DNA and circulating tumour cells isolated from the same preserved whole blood sample. Mol Oncol
2016;10:566-74.
31.    van Dessel LF, Beije N, Helmijr JC, et al. Application of circulating tumor DNA in prospective
clinical oncology trials - standardization of preanalytical conditions. Mol Oncol 2017;11:295-304.
32.    van Dessel LF, van Riet J, Smits M, et al. The genomic landscape of metastatic castration-
resistant prostate cancers reveals multiple distinct genotypes with potential clinical impact. Nat
Commun 2019;10:5251.
33.    Fournier JE, Northrup V, Clark C, et al. Evaluation of BD Vacutainer(R) Barricor blood collection
tubes for routine chemistry testing on a Roche Cobas(R) 8000 Platform. Clin Biochem 2018;58:94-9.
34.    O'Reilly MW, Taylor AE, Crabtree NJ, et al. Hyperandrogenemia predicts metabolic phenotype in
polycystic ovary syndrome: the utility of serum androstenedione. J Clin Endocrinol Metab 2014;99:1027-
36.
35.    O'Reilly MW, Kempegowda P, Jenkinson C, et al. 11-Oxygenated C19 Steroids Are the
Predominant Androgens in Polycystic Ovary Syndrome. J Clin Endocrinol Metab 2017;102:840-8.
36.    Quanson JL, Stander MA, Pretorius E, Jenkinson C, Taylor AE, Storbeck KH. High-throughput
analysis of 19 endogenous androgenic steroids by ultra-performance convergence chromatography
tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2016;1031:131-8.
37.    van der Pas R, Hofland LJ, Hofland J, et al. Fluconazole inhibits human adrenocortical
steroidogenesis in vitro. J Endocrinol 2012;215:403-12.
38.    Prete A, Taylor AE, Bancos I, et al. Prevention of Adrenal Crisis: Cortisol Responses to Major
Stress Compared to Stress Dose Hydrocortisone Delivery. J Clin Endocrinol Metab 2020;105.
39.    Juhlen R, Idkowiak J, Taylor AE, et al. Role of ALADIN in human adrenocortical cells for oxidative
stress response and steroidogenesis. PLoS One 2015;10:e0124582.

40.    Agency EM. Guideline on Bioanalytical Method Validation. 2011.

41.    Kaufman JM, Vermeulen A. The decline of androgen levels in elderly men and its clinical and

therapeutic implications. Endocr Rev 2005;26:833-76.

42.    Keski-Rahkonen P, Huhtinen K, Poutanen M, Auriola S. Fast and sensitive liquid chromatography-

mass spectrometry assay for seven androgenic and progestagenic steroids in human serum. J Steroid

Biochem Mol Biol 2011;127:396-404.

43.    Bruning PF, Jonker KM, Boerema-Baan AW. Adsorption of steroid hormones by plastic tubing. J

Steroid Biochem 1981;14:553-5.

**Acknowledgements**

Funding for this project was provided by the Daniel den Hoed foundation.

The authors thank the volunteers and patients who made this study possible.

**Author Information**

These authors contributed equally: Gido Snaterse and Lisanne F van Dessel.

**Author Contributions**

G.S. performed the LC-MS/MS experiments, data analysis, prepared figures/tables and wrote the

manuscript. L.F.D. collected the patient samples, performed data analysis, prepared figures/tables and

wrote the manuscript. A.E.T. oversaw the LC-MS/MS experiments and analysis of the data, and critical

revision of the manuscript. W.A. was involved in interpretation of the data and critical revision of the

manuscript. M.P.L. was involved in the design of the work, collection of the samples and critical revision

of the manuscript. J.A.V and J.H. were involved in the design of the work, interpretation of the data, and

critical revision of the manuscript.

All authors reviewed and approved the final version of the manuscript.

**Corresponding author**

Correspondence to Johannes Hofland.

**Conflict of Interest**

M.P.L. is the recipient of grants of Sanofi, Johnson & Johnson and Astellas. Other authors did not declare

a conflict of interests.

**Data Availability**

The datasets generated during and/or analysed during the current study are available from the

corresponding author on reasonable request.

**Table 1 – Characteristics of HCs and mCRPC patients**

*Abbreviations*: HCs - healthy controls, mCRPC – metastatic castration-resistant prostate cancer

| | HCs | mCRPC patients |
|---|---|---|
| **N** | 10 | 10 |
| **Age (median (range))** | 32 (25 - 56) | 64 (59 - 76) |
| **Androgen Deprivation Therapy (n)** | | **10** |
| Leuproreline | | 4 |
| Gosereline | | 4 |
| Bilateral orchiectomy | | 2 |
| **Current second-line treatment (n)** | | **6** |
| Enzalutamide | | 3 |
| Apalutamide | | 1 |
| Abiraterone + Prednisone | | 1 |
| Prednisone | | 1 |

**Table 2 – Relative differences in CS and MSP samples compared to serum samples.**

Relative differences are shown as mean ± SD. Statistical comparison was performed by repeated

measurement 1-way ANOVA with post-hoc Dunnett's Test. *p<0.05, ** p<0.01, ***p<0.001.

Abbreviations: CS – CellSave Preservative, DHEA – dehydroepiandrosterone, DHT – 5α-

dihydrotestosterone, HC – Healthy Control, mCRPC – metastatic castration-resistant prostate cancer,

MSP – mechanically separated plasma

| | Healthy Controls (n = 10) | | | mCRPC (n = 10) | | |
|---|---|---|---|---|---|---|
| | Serum Range nmol/L | CS Rel. Difference mean (SD) % | MSP Rel. Difference mean (SD) % | Serum Range nmol/L | CS Rel. Difference mean (SD) % | MSP Rel. Difference mean (SD) % |
| Corticosterone | 2.32 - 32.71 | -20.08 (16.6) ** | 2.6 (11) | 0.55 - 25.34 | -12.3 (13.3) * | -2.8 (9.8) |
| 17-hydroxyprogesterone | 0.37 - 3.75 | -14.4 (15.3) * | 3.16 (16.26) | 0.1 - 1.75 | -3.2(24.1) | -2.2 (9.4) |
| Cortisol | 149.1 - 475.7 | -13.7 (6.1) *** | -0.14 (3.5) | 7.43 - 504.6 | -12.7 (17.9) ** | -1.3 (16.1) |
| Cortisone | 36.35 - 79.4 | -10.8 (6.3) *** | -2 (9.2) | 0.1 - 80.81 | -17.9 (17.2) ** | -1.5 (10.5) |
| DHEA | 0.69 – 36.14 | -0.17 (18.8) | 28.7 (46.6)* | <LOQ – 1.7 | -17.7 (16.5) | 6.0 (12.2) |
| Androstenedione | 2.33 - 6.05 | -15.85 (13.5) ** | 6.9 (9.5) | 0.48 - 3.19 | - 21.2 (14.01) ** | 6.34 (10.4) |
| Testosterone | 7.47 - 17.74 | -11.48 (2.8) *** | 0.82 (4.7) | 0.13 - 0.78 | -16.9 (24.3) * | -2.8 (30.6) |
| DHT | 0.66 - 1.64 | -11.26 (29.2) | -3.5 (30.4) | <LOQ | <LOQ | <LOQ |

**Figure 1. CS and MSP samples compared to serum samples in healthy controls and mCRPC patients.**

Steroid concentrations from serum, CS and MSP samples obtained from ten HCs and ten mCRPC patients

measured by LC-MS/MS. Bland-Altman plots show the relative difference of CS (black) and MSP (gray)

measurements compared to serum. Continuous lines show the mean difference and dotted lines show

the upper- and lower limits of the 95% confidence interval.

*Abbreviations*: CS – CellSave Preservative, DHEA – dehydroepiandrosterone, HC – Healthy Control,

mCRPC – metastatic castration-resistant prostate cancer, MSP – mechanically seperated plasma

**Figure 2 – Circulating steroid concentrations in serum of HCs and mCRPC subjects.**

Steroid hormone concentrations in healthy controls (n = 10) and mCRPC patients (n = 10). Four patients

received no additional treatment, four received antiandrogens (enzalutamide (n=3) or apalutamide

(n=1)), one received abiraterone and prednisone and one received prednisone. Line and error represent

mean ± SEMs.

*Abbreviations*: 17OHP – 17-hydroxyprogesterone, A4 – androstenedione, B – corticosterone, DHEA –

dehydroepiandrosterone, mCRPC – metastatic castration-resistant prostate cancer, E – cortisone, F –

cortisol, T – testosterone

**Figure 3 – Correlations between CS samples and MSP samples with serum samples.**

Deming regression analysis between measurements from serum and CS samples and between serum

and MSP samples in HC and mCRPC patients combined. Corticosterone, DHEA and testosterone values

did not pass normality testing (D'Agostino and Pearson), but did so after logarithmic transformation.

Regression equations for testosterone are presented separately for HCs and mCRPC patients due to the

bimodal distribution resulting from ADT. For DHT, only HC values were used as values in CRPC patients

were below the LLOQ.

*Abbreviation*s: ADT – androgen deprivation therapy, CS – CellSave Preservative, DHEA –

dehydroepiandrosterone, DHT – Dihydrotestosterone, HC – healthy controls, LLOQ – lower limit of

quantification, mCRPC – metastatic castration-resistant prostate cancer, MSP – mechanically separated

plasma.